The expression of HLA class I antigen in prostate cancer in relation to tumor differentiation and patient survival.
The expression of HLA class I antigens was studied using the immunoperoxidase technique on 30 patients with prostate cancer and 29 patients with benign prostatic hypertrophy (BPH). Forty-three percent of the tumors stained positive, in contrast to 21% of the BPH. An inverse relationship was noted between class I expression and degree of tumor differentiation: 88% of the well-differentiated tumors (8/9) expressed class I antigen, compared with 33% (3/9) of the moderately differentiated and 16% (2/12) of the poorly differentiated tumors. No significant survival difference was found between those with class I-positive and -negative tumors. However, when both class I expression and degree of differentiation were considered, those with positive tumors at each level of differentiation had better survival than those with negative tumors. These data suggest that HLA class I expression may serve as a finite prognostic factor and may have relevance in future immunotherapy.
Levin
I
I
Department of Urology, Soroka Medical Center, Beer Sheva, Israel.
Klein
T
T
Kuperman
O
O
Segal
S
S
Shapira
J
J
Gal
R
R
Hart
Y
Y
Klein
B
B
D000230:Adenocarcinoma / Q000276:immunology* / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D016009:Chi-Square Distribution; D015972:Gene Expression Regulation, Neoplastic; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology*; D016019:Survival Analysis
D015395:Histocompatibility Antigens Class I